Results 31 to 40 of about 3,769 (208)

Biological and antimicrobial properties of the association Ambroxol and a water-soluble viscous liquid as a vehicle for a tricalcium silicate-based sealer

Journal of Materials Science: Materials in Medicine, 2021
This study aimed to investigate the antimicrobial and biological properties of Ambroxol associated with glycerin (GLI), propylene glycol (PG), and polyethylene glycol (PEG) as a possible vehicle for an experimental tricalcium silicate sealer, with the ...
Índia Olinta de Azevedo Queiroz, Thiago Machado, Camila Carneiro Alves, Victor Gustavo Balera Brito, Bruno Carvalho de Vasconcelos, João Eduardo Gomes-Filho, Edilson Ervolino, Sandra Helena Penha de Oliveira, Marco Antonio Hungaro Duarte   +8 more
doaj   +1 more source

Pharmacokinetics of Ambroxol Sustained Release (Mucosolvan® Retard) Compared with Other Formulations in Healthy Volunteers

Pulmonary Therapy, 2020
Plain Language Summary Ambroxol is used to relieve the symptoms of respiratory conditions in which abnormal mucus secretion is a problem, including the common cold, acute and chronic bronchitis, and chronic obstructive pulmonary disease.
Celine Ollier, Ulrike Sent, Margarida Mesquita, Martin C. Michel   +3 more
doaj   +1 more source

Mucolitic Ambroxol Versus Hypertonic Saline Nebulizer Induction: For Increasing Sputum Volume And Finding Acid-Fast Bacilli [PDF]

, 2014
Introduction: Tuberculosis, a major killer disease in the community, was caused by Mycobacterium tuberculosis. According to WHO (2006), pulmonary tuberculosis cases in Indonesia was third ranked in the world.
Kristin, Erna, Ang, Sunarto, -, Sumardi
core   +1 more source

Development and Validation of Salbutamol, Bromhexine, Ambroxol and Guauaifenesin Determination in Human Plasma by HPLC-MS/MS Method

Разработка и регистрация лекарственных средств, 2019
Introduction. Multicomponent oral drugs containing salbutamol, bromhexine, ambroxol and guaifenesin have a mucolytic, expectorant and bronchodilator effect.
T. N. Komarov, D. S. Bogdanova, O. A. Miskiv, A. V. Aleshina, I. E. Shohin, Yu. V. Medvedev, N. S. Bagaeva, I. M. Korenskaya   +7 more
doaj   +1 more source

Ambroxol Improves the Broncho-spasmolytic Activity of Clenbuterol in the Guinea-Pig

, 1997
The effects of ambroxol on the spasmolytic action of clenbuterol were investigated on acetylcholine-induced bronchospasm in guinea-pigs. Ambroxol (50 mg kg−1 day−1) or vehicle was administered orally for 14 days. Approximately 45 min after
Peter Engelmann, Gerhard Rauber, Hubertus von Nicolai, Pascal Champeroux, Günther Engelhardt, Michel Pairet, Serge Richard   +6 more
core   +1 more source

Therapy in Bronchopulmonary Diseases Associated with Increased Secretion of Viscous Sputum and Impaired Mucus Transport

Zdorovʹe Rebenka, 2015
The article deals with the problem of cough in bronchopulmonary diseases, in particular, the attention is paid to cough with increased secretion of viscous sputum, i.e., productive cough.
Yu.V. Marushko, M.H. Hrachova
doaj   +1 more source

Value of ambroxol in the treatment of asthmatic bronchitis

Pakistan Journal of Medical Sciences, 2020
Objective: To investigate the clinical effect of ambroxol in the treatment of asthmatic bronchitis. Methods: One hundred and twenty patients with asthmatic bronchitis who were admitted to our hospital from June 2017 to August 2018 were selected as the research subjects and divided into a control group and an observation group according to random ...
Du, Xiaoxia, Zhao, Chengyan, Liu, Shiqing, Su, Shufen   +3 more
openaire   +3 more sources

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ambroxol Hard-Boiled Lozenges in Patients with Acute Pharyngitis

Pulmonary Therapy, 2019
Introduction The aim of this study was to evaluate the efficacy and safety of a new hard-boiled lozenge formulation containing ambroxol 20 mg versus placebo for the relief of sore throat in patients with acute pharyngitis.
Rita Sousa, Deepak R. Lakha, Sandrine Brette, Simon Hitier   +3 more
doaj   +1 more source

The Race to Salvage Glucocerebrosidase: Understanding Small-Molecule Therapies for GBA1-Associated Parkinsonism. [PDF]

Mov Disord
Variants in GBA1, the gene encoding the lysosomal enzyme glucocerebrosidase, cause Gaucher disease and confer an increased risk for parkinsonism. Strategies using small molecules can improve the function of glucocerebrosidase in lysosomes. A clear understanding of the mechanism‐of‐action of these compounds will facilitate development of GBA1‐modulating
Henderson MJ, Chen TC, Glasstetter LM, Chen Y, Marugan JJ, Sidransky E.   +5 more
europepmc   +2 more sources

Feeding of ambroxol ameliorates neurodevelopmental defects and ER stress in the mutated hGBA induced Drosophila eye.

, 2013
Ambroxol can recover morphological defects and decrease ER stress in transgenic flies. (A) Less fluorescence emitted by the eye imaginal discs of hGBARecNciI transgenic combinations treated with, than without 1 mM Ambroxol.
Hyung Don Ryoo (440989), Masami Shimoda (387922), Norio Ishida (24795), Shoji Tsuji (236687), Mitsutoshi Setou (119915), Terumi Yamaguchi (440988), Shuji Hanai (440984), Tomoki Kato (440986), Kumpei Ito (387921), Hidenobu Aizawa (440985), Kazunori Kawasaki (440987), Naoko Goto-Inoue (119884), Takahiro Suzuki (88656)   +12 more
core   +1 more source